

# The effectiveness of behavioral activation for persons with a psychotic disorder and negative symptoms: a multicentre randomized controlled trial

Gepubliceerd: 04-12-2014 Laatst bijgewerkt: 15-05-2024

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Anders
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON23158

### Bron

NTR

### Verkorte titel

BANS

### Aandoening

Schizophrenia, psychosis, behavioral activation, negative symptoms  
Schizofrenie, psychose, behavioral activation, negatieve symptomen

### Ondersteuning

**Primaire sponsor:** GGZ Friesland

RijksUniversiteit Groningen

**Overige ondersteuning:** Self funding

RijksUniversiteit Groningen

### Onderzoeksproduct en/of interventie

## **Uitkomstmaten**

### **Primaire uitkomstmaten**

Degree of negative symptoms

## **Toelichting onderzoek**

### **Achtergrond van het onderzoek**

Negative symptoms are highly prevalent in psychotic disorders and have been associated with poor prognosis, lower social functioning and reduced quality of life. Despite the attention these symptoms receive, so far no evident treatment strategies are available. Major depression shares several features with negative symptoms: loss of goal directed behavior and amotivation. Moreover, anticipatory pleasure, or the ability to experience pleasure related to future activities, is diminished in both. Behavioral activation (BA) is a well-researched and effective treatment strategy for depression. BA focuses on stimulating behavior, in which therapist and patient cooperatively analyse potential rewarding activities and plan these activities subsequently. Recent pilot data showed that behavioral activation might be effective in patients with negative symptoms in schizophrenia.

Primary objective of the study is to investigate whether Behavioral Activation for Negative Symptoms (BANS) improves negative symptoms. Secondary objective is to investigate whether effects of BANS on negative symptoms is mediated or moderated by the ability to experience anticipatory pleasure. We also want to examine whether improvement in negative symptoms is associated with frontal hypo-activity. Finally, we want to examine whether Behavioral Activation for Negative Symptoms leads to better social functioning, improved quality of life and objective increase in activities.

### **Onderzoeksopzet**

T0: baseline assessment

T1: post treatment assessment (15 weeks)

T2: follow-up assessment (6 months)

### **Onderzoeksproduct en/of interventie**

Participants in the treatment condition will receive the Behavioral Activation for Negative Symptoms (BANS). This behavioral therapy focuses on regaining activities. Increased pleasurable activities and associated reward, is expected to diminish apathy. The therapy will consist of 15 hours of individual therapy, carried out by a nurse. In this therapy, the activity level of the patient increases gradually, with activities that are in accordance with patients personal life values.

Participants in the control group will receive 15 weekly individual sessions of befriending,

carried out by a nurse.

## Contactpersonen

### Publiek

GGZ Friesland, afdeling WO&O/RijksUniversiteit Groningen

Aaltsje Malda  
Sixmastraat 2

Leeuwarden 8932 PA  
The Netherlands

### Wetenschappelijk

GGZ Friesland, afdeling WO&O/RijksUniversiteit Groningen

Aaltsje Malda  
Sixmastraat 2

Leeuwarden 8932 PA  
The Netherlands

## Deelname eisen

### Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Primary diagnosis of schizophrenia or schizoaffective disorder (DSM-IV-TR)
- Mild to severe negative symptoms negative symptoms, measured by Positive And Negative Syndrome Scale (PANSS, > 15 on Negative Syndrome Scale)
- 18-65 years old
- Ability to give informed consent

### Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Co-morbid neurological disorder

- Substance dependence (not substance abuse)

## Onderzoeksopzet

### Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Enkelblind
Controle:	Geneesmiddel

### Deelname

Nederland	
Status:	Anders
(Verwachte) startdatum:	01-12-2014
Aantal proefpersonen:	148
Type:	Onbekend

## Ethische beoordeling

Positief advies	
Datum:	04-12-2014
Soort:	Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID:	40340
Bron:	ToetsingOnline
Titel:	

## **Andere (mogelijk minder actuele) registraties in dit register**

Geen registraties gevonden.

## **In overige registers**

<b>Register</b>	<b>ID</b>
NTR-new	NL4871
NTR-old	NTR4989
CCMO	NL47108.042.13
OMON	NL-OMON40340

## **Resultaten**